Is NMN safe with chronic kidney disease (CKD)?

Caution required. NMN is metabolised primarily through liver and tissue enzymes, but NAD+ metabolites are excreted via kidneys. Patients with reduced glomerular filtration rate (GFR) clear water-soluble compounds more slowly. There is no direct trial evidence of NMN safety in CKD stages 3-5. Animal data in CKD models has mixed results - some studies suggest NAD+ replenishment supports residual kidney function; others show no effect. The risk of NMN harming kidney function in CKD is theoretically low because NMN itself is not nephrotoxic at standard doses, but the absence of human trial data in this population means uncertainty. Practical Malaysian protocol: if you have CKD stage 1-2 (GFR > 60), NMN is reasonable with usual safety practice - monitor creatinine and GFR every 3 months, tell your nephrologist. If you have CKD stage 3a-3b (GFR 30-59), discuss with your nephrologist before starting; consider 250mg rather than 500mg as the cap. For CKD stage 4-5 (GFR < 30) or dialysis, defer NMN until further data is available - these patients have multiple medication adjustments and any new agent introduces unnecessary variables. UMMC, IJN, and HKL nephrology departments are increasingly familiar with the question as more middle-aged patients ask. The honest answer to those patients is usually 'we don't know enough yet, prioritise your prescribed regimen first'. Diabetes-driven CKD is a particularly common Malaysian scenario; in that case, glycaemic control via prescribed therapy outranks any NMN benefit.

Why this matters for Malaysian buyers

NMN buying decisions in Malaysia involve a stack of considerations that don't always map to advice from US- or EU-focused sources: NPRA notification status, JAKIM halal certification (or its absence), tropical-climate storage realities, mall pharmacy versus Shopee Malaysia tradeoffs, and how local medical practitioners typically respond to questions about supplements outside their training. We answer questions like "Is NMN safe with chronic kidney disease (CKD)?" through the lens of Malaysian buyer realities - not generic global guidance.

Verify the source

This individual Q&A is a supporting note, not an indexable authority article. Health-relevant claims should be refreshed against the linked primary or official sources before they are used for buying or medical discussions.

• Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects (2022)
• Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women (2022)
• The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial (2023)
• National Pharmaceutical Regulatory Agency (NPRA) Malaysia - Quest3+ MAL Number Registry (2026)
• Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (2021)
• Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging (2013)

Adjacent tools

Need to act on this answer? Try the halal checker, the cost calculator, the stack builder, or the brand selector quiz - each tool turns advice into actionable output for your specific situation.

More questions? Browse the full Q&A library (10 categories) · See our main FAQ · Browse NMN brand comparisons · NR brand comparisons.